Praxis Precision Medicines, Inc. PRAX Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Praxis Precision Medicines, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The official record: Praxis Precision Medicines, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Praxis Precision Medicines, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Praxis Precision Medicines, Inc.'s cash & equivalents?
- Praxis Precision Medicines, Inc. (PRAX) reported cash & equivalents of $536.75M in Q1 2026.
- How has Praxis Precision Medicines, Inc.'s cash & equivalents changed year-over-year?
- Praxis Precision Medicines, Inc.'s cash & equivalents increased by 223.4% year-over-year, from $165.98M to $536.75M.
- What is the long-term trend for Praxis Precision Medicines, Inc.'s cash & equivalents?
- Over 5 years (2020 to 2025), Praxis Precision Medicines, Inc.'s cash & equivalents has grown at a 3.8% compound annual growth rate (CAGR), from $297.21M to $357.75M.
- What does cash & equivalents mean?
- The total amount of cash and highly liquid investments a company holds that can be accessed immediately.
- How do you interpret cash & equivalents?
- An increase suggests improved liquidity and a longer operational runway, while a decrease indicates cash burn from operations or capital expenditures.
- How does cash & equivalents compare across companies?
- Peers in the clinical-stage biotech sector typically maintain high cash balances to support multi-year drug development cycles.